Myriad Genetics (MYGN) Form 4: 4,435 Shares Withheld for Taxes

Jennifer Lynne Fox, identified as Chief Legal Officer and a director of Myriad Genetics, reported a transaction dated 09/03/2025 on Form 4.

Rhea-AI Filing Summary

Jennifer Lynne Fox, identified as Chief Legal Officer and a director of Myriad Genetics, reported a transaction dated 09/03/2025 on Form 4. The filing shows 4,435 shares of Myriad common stock were withheld at a price of $6.80 per share to satisfy tax withholding obligations related to the vesting of restricted stock units. After the withholding, the reporting person beneficially owned 120,481 shares directly. The form was signed on behalf of the reporting person by Justin Hunter on 09/04/2025.

Positive

• Compliance: The filing documents tax-withholding tied to RSU vesting, showing adherence to reporting requirements.
• Transparency: The report discloses the exact number of shares withheld and the post-transaction beneficial ownership.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding on vested restricted stock units; consistent with standard executive compensation mechanics.

The Form 4 documents a withholding of 4,435 shares to cover tax obligations arising from RSU vesting. This is an administrative action rather than an open-market sale and does not indicate a change in company control or new disposition strategy. The reporting person remains a significant direct holder with 120,481 shares after the withholding.

Securities Analyst

TL;DR: Transaction is non-dispositive and unlikely to be material to investors given its size relative to total holding.

The code F transaction reflects shares withheld by the issuer for tax purposes at $6.80 per share. Such withholdings accompany RSU vesting and reduce the reported share count without an open-market trade. No derivative activity or additional transfers are disclosed in this filing.

Insider Trade Summary

Exercise Price or Tax Liability: 4,435 shares

Exercise Price or Tax Liability 1 txn

Insider Fox Jennifer Lynne

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	4,435	$6.80	$30K

Holdings After Transaction: Common Stock — 120,481 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 3, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Myriad Genetics (MYGN) Form 4 filed by Jennifer Lynne Fox report?

The Form 4 reported that 4,435 shares were withheld at $6.80 per share to satisfy tax withholding on vested restricted stock units.

When was the transaction in the MYGN Form 4 executed?

The transaction date is 09/03/2025, and the form shows a signature submission dated 09/04/2025.

How many Myriad shares does Jennifer Lynne Fox beneficially own after the transaction?

After the withholding, the reporting person beneficially owned 120,481 shares directly.

Was the Form 4 transaction an open-market sale or a withholding to cover taxes?

The filing indicates a code F transaction, meaning shares were withheld by the company to satisfy tax withholding obligations, not sold on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jennifer Lynne

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		F		4,435(1)	D	$6.8	120,481	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 3, 2025.

Remarks:

	By: Justin Hunter For: Jennifer Lynne Fox	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.